Affiliation:
1. Department of Pharmaceutical Quality Assurance, B. K. Mody Government Pharmacy Collage, Rajkot, Gujarat, 360003.
Abstract
Post-covid-19 women complications, Post covid-19 is Clinical symptoms that persist or worsen after acute COVID It is contains both ongoing symptomatic COVID-19 between 4 to 12 weeks or post COVID-19 more than 12 weeks. As of June 2020, given the terminology "post COVID-19". Reported studies are related to complications of the female patient, including effects on the immune system, physiology, or psychological health, and effects on pre-existing diseases, including hypertension, diabetes mellitus, neurodegenerative disease, rheumatoid arthritis, and tuberculosis (TB). However, six months after recovery from COVID-19, complications arise, including cough, fever, breathlessness, muscle aches, joint pain, fatigue, gastrointestinal complaints, anosmia, dyspepsia, sleep difficulties, anxiety or depression, higher stress levels, physical decline, post-activity polypnea, alopecia, chest tightness, palpitations, intestinal blockages, impaired respiratory functions, neurological issues, olfactory dysfunction, cognition, dexterity, conversation, disabilities of sight, or listening. Along with other miscellaneous complications such as Miller-Fisher syndrome. Overall, these reviews summarise studies conducted on pre-existing diseases in female patients after COVID-19, complications in female patients with immune dysfunction, including hormonal imbalances, and CSF-insufficiency in female patients with neurodegeneration complications. It observed high levels of molecular markers such as tau protein (t-tau, p-tau), plasma amyloid-beta (A42), glial fibrillary acidic protein (GFAP), ubiquitin C-terminal hydrolase-L1 (UCH-L1), neurofilament light chain protein. In Female patients with diabetes mellitus (Type 1 and Type 2) complications reported higher levels of sCr, C-reactive protein, TN-I, white blood cell, and erythrocyte sedimentation rate levels, enzymes, electrolytes, and coagulation factors, and female patients with tuberculosis (TB) complications had lower aggressive angiomyxoma (AAM) and E2 hormone levels.